Citations

Clear

861 citation(s) found for "Sd, Wexner".

Stability of One-Step Spray-on Splint for Lower Extremity Fractures During Splinting, MEDEVAC, and Impact
Hobayan, Catherine Grace , Heyniger, John, Alzouhayli, Kenan , Piscitani, Franco , Haider, Clifton R. , Felton, Christopher L. , Groth, Adam T. , Bates, Nathaniel A , Felton, Christopher, Felton, Christopher L , Bates, Nathaniel A. , Martin, Kevin D.

Mayo Clinic

Military Medicine | January 31, 2024 | Volume: 189 | Issue: 9-10 | Pages: 1947-1954

10.1093/milmed/usae001 | PMID 38294066 Get It

ABSTRACT Introduction Military transport can induce whole-body vibrations, and combat almost always involves high impact between lower extremities and the ground. Therefore, robust splinting technology is necessary for lower extremity fractures in these settings. Our team compared a novel one-step spray-on foam splint (FastCast) to the current military standard structured aluminum malleable (SAM) splint. Materials and Methods Ten cadaveric specimens were subjected to complete tibia/fibula osteotomy. Specimens were fitted with custom accelerometer and gyroscope sensors superior and inferior to the fracture line. Each specimen underwent fracture and splinting from a standard of care SAM splint and an experimental FastCast spray foam splint in a randomized order. Each specimen was manually transported to an ambulance and then released from a 1 meter height to simulate impact. The custom sensors recorded accelerations and rotations throughout each event. Repeated-measures Friedman tests were used to assess differences between splint method within each event and between sensors within each splint method. Results During splinting, overall summation of change and difference of change between sensors for accelerations and rotations were greater for SAM splints than FastCast across all axes (P ≤ 0.03). During transport, the range of acceleration along the linear superior/inferior axis was greater for SAM splint than FastCast (P = 0.02), as was the range of rotation along the transverse plane (P < 0.01). On impact, the summation of change observed was greater for SAM splint than FastCast with respect to acceleration and rotation on the posterior/anterior and superior/inferior axes (P ≤ 0.03), and the cumulative difference between superior and inferior sensors was greater for SAM than FastCast with respect to anterior-axis rotation (P < 0.05). Conclusion FastCast maintains stabilization of fractured lower extremities during transport and impacts to a significantly greater extent than SAM splints. Therefore, FastCast can potentially reduce the risk of fracture complications following physical stressors associated with combat and extraction.
Systemic Neutrophil Gelatinase-Associated Lipocalin Alterations in Chronic Pancreatitis: A Multicenter, Cross-Sectional Study
Torok, Molly, Pfau, Timothy, Mace, Thomas A. , Cole, Rachel M. , Hart, Phil A. , Krishna, Somashekar G. , Lara, Luis F. , Ramsey, Mitchell L. , Fogel, Evan L. , Forsmark, Chris E. , Li, Liang , Park, Walter G. , Vege, Santhi Swaroop , Yadav, Dhiraj , Conwell, Darwin L. , Cruz‐Monserrate, Zobeida , Krishna, Somashekar G , Gumpper, Kristyn , Chasser, Kaylin M. , Pita-Grisanti, Valentina , Belury, Martha Ann , Culp, Stacey , Fisher, William P. , Pandol, Stephen J. , Serrano, José , Van Den Eeden, Stephen K

Mayo Clinic

Clinical and Translational Gastroenterology | January 29, 2024 | Volume: 15 | Issue: 4 | Pages: e00686

10.14309/ctg.0000000000000686 | PMID 38284831 Get It

INTRODUCTION: Chronic pancreatitis (CP) is a progressive fibroinflammatory disorder lacking therapies and biomarkers. Neutrophil gelatinase-associated lipocalin (NGAL) is a proinflammatory cytokine elevated during inflammation that binds fatty acids (FAs) such as linoleic acid. We hypothesized that systemic NGAL could serve as a biomarker for CP and, with FAs, provide insights into inflammatory and metabolic alterations. METHODS: NGAL was measured by immunoassay, and FA composition was measured by gas chromatography in plasma (n = 171) from a multicenter study, including controls (n = 50), acute and recurrent acute pancreatitis (AP/RAP) (n = 71), and CP (n = 50). Peripheral blood mononuclear cells (PBMCs) from controls (n = 16), AP/RAP (n = 17), and CP (n = 15) were measured by cytometry by time-of-flight. RESULTS: Plasma NGAL was elevated in subjects with CP compared with controls (area under the curve [AUC] = 0.777) or AP/RAP (AUC = 0.754) in univariate and multivariate analyses with sex, age, body mass index, and smoking (control AUC = 0.874; AP/RAP AUC = 0.819). NGAL was elevated in CP and diabetes compared with CP without diabetes ( P < 0.001). NGAL + PBMC populations distinguished CP from controls (AUC = 0.950) or AP/RAP (AUC = 0.941). Linoleic acid was lower, whereas dihomo-γ-linolenic and adrenic acids were elevated in CP ( P < 0.05). Linoleic acid was elevated in CP with diabetes compared with CP subjects without diabetes ( P = 0.0471). DISCUSSION: Elevated plasma NGAL and differences in NGAL + PBMCs indicate an immune response shift that may serve as biomarkers of CP. The potential interaction of FAs and NGAL levels provide insights into the metabolic pathophysiology and improve diagnostic classification of CP.
P433 Short-term outcomes of surgical treatment in primary ileocecal Crohn’s disease patients. Results of Crohn’s(urg) study, multicenter, retrospective, comparative analysis between indications for luminal and complicated phenotype
Bislenghi, Gabriele , D’Hoore, André , Juachon, Patrizia, Harsløf, Sanne , Gomez, Joanne Michelle D. , Merchea, Amit , Shacker, A, Gallostra, M Marti, Maruyana, B Yuki, Garoufalia, Zoe , Zhihui, C, Rrupa, Djana , Haanappel, Anouck , Giorgi, Lorenzo , Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Tottrup, A, Colpaert, J, Giorgi, L, Overstraeten, Anthony de Buck van , Olivera, Pablo Andres , Gomez, J, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Gallostra, M Marti, Kraft, Miquel , Kotze, Paulo Gustavo , Wexner, Steven D. , Zhihui, C, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, K, Christensen, Peter , Spinelli, Antonino

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i881-i883

10.1093/ecco-jcc/jjad212.0563 Get It

Abstract Background Recent evidence challenges the current standard of offering surgery to patients with ileocecal Crohn’s disease only when they present complications of the disease. Methods A retrospective, multicenter comparative analysis was performed including patients operated for primary ileocecal CD at 12 referral centers. Patients were divided in 2 groups, according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short-term results were compared. Patients operated on for primary isolated ileocaecal CD (last 50 cm of the terminal ileum and cecum), either for predominantly inflammatory phenotype or for complications of the disease (stricturing or fistulizing pattern), between January 2012 - December 2021 were considered eligible to participate in this study. Patients with previous abdominal procedures for CD, and patients who had activity of the disease in other intestinal segments other than the ileocaecal region at the time of surgery, were excluded from the study. Results 2013 patients were included, 291 (14.5%) in the ICD group. No differences were found between groups in time from diagnosis to surgery or in the levels of exposure to biologic drugs before indication of surgery. CCD patients had higher rates of low BMI, anemia (40.9 vs. 27%, p: &lt; 0.001), and low albumin (11.3 vs. 2.6%, p: &lt; 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3 vs. 93.1%, p: 0.001), and higher conversion rates (9.3 vs. 1.9%, p: &lt; 0.001). CCD had longer hospital stay and higher postoperative complication rates (26.1 vs. 21.3%, p: 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1 vs. 8.3%, p: 0.017). In multivariate analysis, CCD was associated with prolonged surgeries (OR: 3.44, p: 0.001) and requirements of multiple intraoperative procedures (OR: 8.39, p: 0.030). Conclusion Indication of surgery in patients who present an inflammatory phenotype of CD was associated with better outcomes when compared to patients operated on for complications of the disease, without a difference between groups in time from diagnosis to surgery.
OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn’s Disease: results from the global ADMIRE-CD II phase 3 study
Šerclová, Zuzana , Chen, Shujun , Fleshner, Phillip , Zhang, Barbara, McKay, C, Nazarey, Pradeep , Raffals, Laura E. , García‐Olmo, Damián , Wexner, Steven D. , Panés, Julián , Wu, C, Colombel, Jean‐Frédéric , Song, Ming , Wright, Emily Kate

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i34-i35

10.1093/ecco-jcc/jjad212.0018 Get It

Abstract Background Complex perianal fistulas are a serious complication in patients with Crohn’s disease (CD). Darvadstrocel (DVS), a suspension of expanded adult allogeneic adipose-derived mesenchymal stem cells, is approved in Europe and Japan for treatment of complex Crohn’s perianal fistulas (CPF). The global ADMIRE-CD II phase 3 randomized double-blind placebo-controlled study evaluated the efficacy and safety of DVS for treatment of complex CPF. Methods Patients aged 18–75 years with clinically controlled, inactive or mildly active CD and complex CPF (≤2 internal openings [IO] and ≤3 external openings [EOs]) who had an inadequate, or a loss of response to immunosuppressive agents or biologics were included. Patients were randomized 1:1 to receive a local injection of DVS as a single dose (120 x 106 cells/24 mL) or placebo. In all patients, fistula preconditioning included vigorous curettage and seton placement 2–3 weeks before treatment, and seton removal, a further curettage and closure of IOs immediately before treatment. The primary endpoint was combined remission (closure of all treated EOs that were draining at baseline, despite gentle finger compression, and absence of collections &gt;2 cm confirmed by MRI) at 24 weeks. Secondary endpoints included combined remission at 52 weeks, clinical remission (closure of all treated EOs without MRI confirmation) at 24 and 52 weeks, and time to clinical remission at 24 weeks. Safety was monitored up to 52 weeks. Results From 19 Oct 2017 to 26 Jul 2023, 568 patients received DVS (n = 283) or placebo (n = 285) with fistula preconditioning; 56.3% of patients enrolled in Europe and Israel, and 43.7% in North America. Mean (SD) age, sex and race were similar in the DVS and placebo arms (38.4 [11.9] vs 37.7 [10.8] years; 42.8% vs 45.6% female; 85.9% vs 89.1% White). Combined remission rates at 24 weeks did not statistically differ between treatments (48.8% DVS vs 46.3% placebo) and there were no differences in secondary endpoints (Table 1; Figure 1). Based on health authority guidelines, post hoc analyses of patients randomized before COVID-19 (11 March 2020; n = 141 DVS, n = 143 placebo) were performed: combined remission rates at 24 weeks were 46.8% (DVS) and 38.5% (placebo). The safety profile for DVS was consistent with prior studies with no new safety signals (Table 1). Conclusion The efficacy outcomes assessed did not statistically differ between DVS and placebo, and the placebo response rate (with fistula preconditioning) was higher than expected. Post hoc analyses revealed lower placebo response rates in patients randomized before COVID-19 (similar to the pivotal ADMIRE CD I study) than the overall placebo arm. DVS was well tolerated.
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Schmults, Chrysalyne D. , Blitzblau, Rachel , Aasi, Sumaira Z. , Alam, Murad , Amini, Arya , Bibee, Kristin , Bolotin, Diana, Chen, Pei-Ling , DiMaio, Dominick J. , Farma, Jeffrey M. , Ghosh, Karthik, Harms, Kelly L. , Lukens, John N. , Manber, Susan, Mark, Lawrence A. , Medina, Theresa , Nehal, Kishwer S. , Patel, Tejesh , Rich, Jason T. , Shaha, Ashok R. , Thomas, Valencia D., Tomblinson, Courtney M. , Venkat, Puja , Xu, Yaohui , Yu, Siegrid S., McCullough, Beth, Espinosa, Sara, Sekulić, Aleksandar , Alam, Murad , Bordeaux, Jeremy S. , Contreras, Carlo M. , Donigan, Jessica M. , Ho, Alan L. , Medina, Theresa Michelle , Nghiem, Paul , Olino, Kelly L. , Park, Soohyung , Puzanov, Igor , Sekulic, Aleksander , Srivastava, Divya , Tomblinson, Courtney, Yusuf, Mehran Behruj

Mayo Clinic

Journal of the National Comprehensive Cancer Network | January 19, 2024 | Volume: 22 | Issue: 1D | Pages: 1-11

10.6004/jnccn.2024.0002 | PMID 38244274 Get It

The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled “Clinical N0 Disease, Locally Advanced MCC.” This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term “nonsurgical” by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL
Woyach, Jennifer A. , Burbano, Gabriela Perez , Ruppert, Amy S. , Heerema, Nyla A. , Zhao, Weiqiang , Wall, Anna, Brander, Danielle M. , Rogers, Kerry A. , Stephens, Deborah M. , Brown, Jennifer R. , Lozanski, Gerard , Nattam, Sreenivasa, Litzow, Mark R. , Luger, Selina M. , Owen, Carolyn , Kuzma, Charles, Little, Richard F. , Dinner, Shira, Stone, Richard M. , Uy, Geoffrey L. , Mandrekar, Sumithra J. , Byrd, John C. , Perez Burbano, Gabriela , Barr, Paul M , Rogers, Kerry A , Parikh, Sameer A , Stephens, Deborah M , Blachly, James , Larson, Richard A , Erba, Harry Paul , Litzow, Mark R. , Abramson, Jeremy S , Little, Richard F , Uy, Geoffrey , Byrd, John C , Miller, Cecelia , Ding, Wei , Bartlett, Nancy L. , Barr, Paul M. , Parikh, Sameer A. , Blachly, James S. , Larson, Richard A. , Abramson, Jeremy S. , Stock, Wendy

Mayo Clinic

Blood | January 12, 2024 | Volume: 143 | Issue: 16 | Pages: 1616-1627

10.1182/blood.2023021959 | PMID 38215395 Get It

Abstract A041202 (NCT01886872) is a phase 3 study comparing bendamustine plus rituximab (BR) with ibrutinib and the combination of ibrutinib plus rituximab (IR) in previously untreated older patients with chronic lymphocytic leukemia (CLL). The initial results showed that ibrutinib-containing regimens had superior progression-free survival (PFS) and rituximab did not add additional benefits. Here we present an updated analysis. With a median follow-up of 55 months, the median PFS was 44 months (95% confidence interval [CI], 38-54) for BR and not yet reached in either ibrutinib-containing arm. The 48-month PFS estimates were 47%, 76%, and 76% for BR, ibrutinib, and IR, respectively. The benefit of ibrutinib regimens over chemoimmunotherapy was consistent across subgroups of patients defined by TP53 abnormalities, del(11q), complex karyotype, and immunoglobulin heavy chain variable region (IGHV). No significant interaction effects were observed between the treatment arm and del(11q), the complex karyotype, or IGHV. However, a greater difference in PFS was observed among the patients with TP53 abnormalities. There was no difference in the overall survival. Notable adverse events with ibrutinib included atrial fibrillation (afib) and hypertension. Afib was observed in 11 patients (pts) on BR (3%) and 67 pts on ibrutinib (18%). All-grade hypertension was observed in 95 pts on BR (27%) and 263 pts on ibrutinib (55%). These data show that ibrutinib regimens prolong PFS compared with BR for older patients with treatment-naïve CLL. These benefits were observed across subgroups, including high-risk groups. Strikingly, within the ibrutinib arms, there was no inferior PFS for patients with abnormalities in TP53, the highest risk feature observed in CLL. These data continue to demonstrate the efficacy of ibrutinib in treatment-naïve CLL.
Postoperative Care of Zenker Diverticula: Contemporary Perspective from the Prospective OUtcomes Cricopharyngeaus Hypertonicity (POUCH) Collaborative
McKeon, Mallory , McCoy, Nicole, Johnson, Christopher , Allen, Jacqui , Altaye, Mekibib , Bayan, Semirra L. , Belafsky, Peter C. , deSilva, Brad W. , Dion, Gregory R. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L. , Matrka, Laura , Mayerhoff, Ross , Piraka, Cyrus , Rosen, Clark A. , Wahab, Shaun A. , Wilson, Keith , Wright, Carter , Young, VyVy N. , Postma, Gregory N. , Howell, Rebecca J. , Bayan, Semirra, Belafsky, Peter , deSilva, Brad , Dion, Greg , Ekbom, Dale , Friedman, Aaron D , Fritz, Mark , Giliberto, John Paul , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Tabangin, Meredith , Young, Vyvy , Howell, Rebecca , Bayan, Semirra , Amin, Milan R , Giliberto, John Paul , Guardiani, Elizabeth , Kwak, Paul E. , Tabangin, Meredith E. , Wilson, Keith, Wright, Carter

Mayo Clinic

The Laryngoscope | December 26, 2023 | Volume: 134 | Issue: 6 | Pages: 2678-2683

10.1002/lary.31226 | PMID 38146791 Get It

Objectives The aim of the study was to identify trends in postoperative management of persons undergoing surgery for Zenker diverticula (ZD) by evaluating length of stay (LOS), diet on discharge, and imaging with or without surgical complication. Methods Prospectively enrolled adult patients with cricopharyngeal muscle dysfunction with diverticula undergoing surgery from August 1, 2017 to February 1, 2023 were included. Data were extracted from a multi‐institutional REDCap database, summarizing means, medians, percentages, and frequencies. Fisher's exact or chi squared analyses were utilized, as appropriate, to compare subsets of data. Descriptive analysis assessed differences in clinical course and the relationship to postoperative management. Results There were 298 patients with a mean (standard deviation) age of 71.8 (11.2) years and 60% male. Endoscopic surgery was performed in 79.5% (237/298) of patients versus 20.5% (61/298) open surgery. Sixty patients (20.1%) received postoperative imaging, with four leaks identified. Complications were identified in 9.4% of cases ( n = 29 complications in 28 patients), more commonly in open surgery. Most (81.2%) patients were discharged within 23 h. About half of patients (49%) were discharged from the hospital on a pureed/liquid diet; 36% had been advanced to a soft diet. In patients without complications, LOS was significantly longer following open cases ( p = 0.002); postoperative diet was not different between open and endoscopic ( p = 0.26). Conclusions Overall, most patients are discharged within 23 h without imaging. However, LOS was affected by surgical approach. Postoperative complications are different in endoscopic versus open surgery. Complications with either approach were associated with prolonged LOS, need for imaging, and diet restriction. Level of Evidence Level III Laryngoscope , 134:2678–2683, 2024
Intradural Pituitary Hemitransposition: Technical Note and Case Series Illustration
Almeida, João Paulo , Finger, Guilherme , Weber, Matthieu D. , Wu, Kyle , Walz, Patrick C. , Leonard, Jeffrey R. , Carrau, Ricardo L. , Prevedello, Daniel M. , Wu, Kyle C , Carrau, Ricardo L , Prevedello, Daniel M , Almeida, Joao Paulo , Damante, Mark A.

Mayo Clinic

Operative Neurosurgery | December 22, 2023 | Volume: 26 | Issue: 6 | Pages: 625-634

10.1227/ons.0000000000001036 | PMID 38132563 Get It

BACKGROUND AND OBJECTIVES: Lesions located in the retrosellar region, interpeduncular cistern, and petroclival region are among the most difficult to access in neurosurgery. Transcranial approaches are useful; however, the large distance between the surgeon and the lesion as well as the presence of major neurovascular structures surrounding the lesion may limit surgical exposure. A midline transsphenoidal route avoids transgression of the neurovascular plane and provides direct access to the interpeduncular cistern. To safely access the interpeduncular fossa, it requires mobilization of the pituitary gland. The pituitary hemitransposition technique permits mobilization of the gland, while preserving its venous drainage and arterial supply to the gland on one of its sides, preserving gland function. The authors aim to describe the intradural pituitary hemitransposition technique and to demonstrate its safe application for resection of skull base tumors in the retrosellar space. METHODS: The authors describe the surgical technique and illustrate its application in 5 cases of different types of skull base tumors, including a video demonstrating all the steps to perform this approach. In addition, the authors discuss the advantages and limitations of this technique compared with other approaches to the retrosellar space. RESULTS: The intradural pituitary hemitransposition technique was used to safely resect a chondrosarcoma, chordoma, craniopharyngioma, teratoma, and meningioma involving the parasellar and retrosellar spaces, while minimizing endocrine morbidity. We had one patient with mild, albeit permanent hyperprolactinemia and hypothyroidism after surgery. No other patients had permanent dysfunction related to surgery. CONCLUSION: The endonasal endoscopic intradural pituitary hemitransposition approach is an effective technique for resection of lesions located within the retrosellar and petroclival regions, allowing adequate exposure while potentially optimizing the preservation of the pituitary function.
The impact of bariatric surgery on admissions for gastrointestinal complications and conditions associated with obesity: A nationwide study
Patel, Arsheya , Hinton, Alice , Krishna, Somashekar G. , Brethauer, Stacy A., Hussan, Hisham , Hussan, Hisham , Krishna, Somashekar G , Dayyeh, Barham K. Abu , Balasubramanian, Gokulakrishnan

Mayo Clinic

World Journal of Surgery | December 16, 2023 | Volume: 48 | Issue: 1 | Pages: 175-185

10.1002/wjs.12013 | PMID 38436211 Get It

AbstractBackgroundObesity worsens various gastrointestinal pathologies. While bariatric surgery ameliorates obesity, it substantially modifies the gastrointestinal system depending on surgery type, with limited data on subsequent impact on obesity‐related gastrointestinal admissions.MethodsUsing the 2012–2014 Nationwide Readmission Database, we included individuals with obesity who received vertical sleeve gastrectomy (VSG), Roux‐en‐Y gastric bypass (RYGB), or hernia repair (HR–control surgery). Our main focus was the adjusted odds ratio (aOR) for gastrointestinal inpatient admissions within 6 months following surgery compared to the 6 months preceding it, while controlling for several confounding factors. Gastrointestinal admissions were grouped into postoperative complications or obesity‐associated gastrointestinal conditions.ResultsOur cohort included 140,103 adults with RYGB, 132,253 with VSG, and 12,436 HR controls. Postoperative gastrointestinal complications were most common after RYGB, prominently obstruction (aOR = 33.17, 95%CI: 18.01, 61.10), and Clostridium difficile infection (aOR: 12.52, 95%CI: 6.22, 25.19). VSG also saw significantly increased but less frequent similar conditions. Notably, for gastrointestinal conditions associated with obesity, acute pancreatitis risk was higher post‐VSG (aOR = 6.26, 95%CI: 4.02, 9.73). Post‐RYGB patients were most likely to be admitted for cholelithiasis with cholecystitis (aOR: 4.15, 95% CI: 3.24, 5.31), followed by chronic liver disease (aOR: 3.00, 95% CI: 2.33, 3.87). The risk of noninfectious colitis admissions was threefold higher after RYGB and VSG. No gastrointestinal conditions showed an increase after HR.ConclusionDespite weight loss, bariatric surgery was associated with an increased risk of hepato‐pancreatobiliary and colitis admissions related to obesity in the first six postoperative months, with considerable variations in rates of gastrointestinal conditions by surgery type.
Efficacy and Safety of Dichlorphenamide for the Treatment of Periodic Paralysis: a Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial (PL02.001)
Burge, J., Sansone, Valeria , Smith, Patty, Herr, Barbara E., Tawil, Alrabi, Pandya, Shree, Kissel, John T., Ciafaloni, Emma , Ralph, Jeffrey , Barohn, Richard J., Mitsumoto, Hiroshi , Pestronk, Alan , Conwit, Robin , Jasek, Mark C, Hanna, Michael G. , McDermott, Michael , Shieh, Perry B. , Amato, Anthony A. , Cannon, Stephen C. , Trivedi, Jaya , Crum, Brian A. , Meola, G. , Griggs, Robert C.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 86 | Issue: 16_supplement | Pages: No page available

10.1212/wnl.86.16_supplement.pl02.001 Get It